predictive correlates response anti-pd-l1 antibody mpdl3280a cancer patients
development human cancer multistep process characterized accumulation genetic epigenetic alterations drive reflect tumour progression changes distinguish cancer cells normal counterparts allowing tumours recognized foreign immune system- however tumours rarely rejected spontaneously reflecting ability maintain immunosuppressive microenvironmen programmed death-ligand pd-li also called b7-h1 cd274 expressed many cancer immune cells plays important part blocking cancer immunity cycle binding programmed death pd- b7 cd80 negative regulators t-lymphocyte activation binding pd-l1 receptors suppresses t-cell migration proliferation secretion cytotoxic mediators restricts tumour cell killing- pd li-pd axis protects host overactive t-effector cells cancer also microbial infections blocking pd-l1 therefore enhance anticancer immunity little known predictive factors efficacy study designed evaluate safety activity biomarkers pd-l1 inhibition using engineered humanized antibody mpdl3280a show across multiple cancer types responses evaluated response evaluation criteria solid tumours version observed patients tumours expressing high levels pd-l1 especially pd-l1 expressed tumour-infiltrating immune cells furthermore responses associated t-helper type th gene expression ctla4 expression absence fractalkine cx3cl1 baseline tumour specimens together data suggest mpdl3280a effective patients pre-existing immunity suppressed pd-l1 re-invigorated antibody treatment
